|
|
Volumn 56, Issue 2, 2015, Pages 395-400
|
|
Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
a
|
|
Author keywords
AML; MDS; Multi kinase inhibitor; SAR103168
|
|
Indexed keywords
ABELSON KINASE;
ANTILEUKEMIC AGENT;
BCR ABL PROTEIN;
MIDAZOLAM;
PHOSPHOTRANSFERASE INHIBITOR;
SAR 103168;
UNCLASSIFIED DRUG;
PROTEIN KINASE INHIBITOR;
PYRIDINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
SAR103168;
ACUTE LEUKEMIA;
ADULT;
ARTICLE;
ASTHENIA;
BACTEREMIA;
BLOOD SAMPLING;
BONE MARROW BIOPSY;
BONE PAIN;
CANCER CHEMOTHERAPY;
COHORT ANALYSIS;
DEEP VEIN THROMBOSIS;
DRUG EXPOSURE;
FEBRILE NEUTROPENIA;
FEMALE;
GOOD CLINICAL PRACTICE;
GOOD LABORATORY PRACTICE;
HUMAN;
LIQUID CHROMATOGRAPHY;
LUNG EMBOLISM;
MAJOR CLINICAL STUDY;
MALE;
MAXIMUM TOLERATED DOSE;
MYELODYSPLASTIC SYNDROME;
PHASE 1 CLINICAL TRIAL;
PHYSICAL EXAMINATION;
PNEUMONIA;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
SEPTIC SHOCK;
SINUSITIS;
SYSTOLIC BLOOD PRESSURE;
TANDEM MASS SPECTROMETRY;
UNITED STATES;
ACUTE DISEASE;
ADOLESCENT;
AGED;
AREA UNDER THE CURVE;
CHEMICALLY INDUCED;
CLINICAL TRIAL;
DIZZINESS;
DOSE RESPONSE;
DRUG RESISTANCE;
HYPOKALEMIA;
LEUKEMIA, MYELOID;
METABOLIC CLEARANCE RATE;
MIDDLE AGED;
MULTICENTER STUDY;
MYELODYSPLASTIC SYNDROMES;
PATHOLOGY;
RISK FACTOR;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
VERY ELDERLY;
YOUNG ADULT;
ACUTE DISEASE;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
AREA UNDER CURVE;
DIZZINESS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
HUMANS;
HYPOKALEMIA;
LEUKEMIA, MYELOID;
MALE;
METABOLIC CLEARANCE RATE;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
NEOPLASM RECURRENCE, LOCAL;
PROTEIN KINASE INHIBITORS;
PYRIDINES;
PYRIMIDINES;
RISK FACTORS;
TREATMENT OUTCOME;
YOUNG ADULT;
|
|
EID: 84923937157
PISSN: 10428194
EISSN: 10292403
Source Type: Journal
DOI: 10.3109/10428194.2014.918970 Document Type: Article |
|
Times cited : (3)
|
|
References (7)
|
